← Back to Clinical Trials
Recruiting NCT06890013

NCT06890013 A Prospective, Single-center, Observational Study Aiming to Assess the Predictive Role of Flow Mediated Dilatation in Acute Coronary Syndromes, Combined With Echocardiographic and Biochemical Indices

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06890013
Status Recruiting
Phase
Sponsor Aristotle University Of Thessaloniki
Condition Acute Coronary Syndromes
Study Type OBSERVATIONAL
Enrollment 100 participants
Start Date 2024-06-01
Primary Completion 2026-06-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 85 Years
Study Type OBSERVATIONAL
Interventions
Observation group

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 100 participants in total. It began in 2024-06-01 with a primary completion date of 2026-06-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

A prospective, single-center, observational study aiming to assess the predictive role of flow mediated dilatation in acute coronary syndromes, combined with echocardiographic and biochemical indices. The novel Cor-IS technology will also be evaluated.

Eligibility Criteria

Inclusion Criteria: 1. Age \> 18 years 2. Patients hospitalized due to acute coronary syndrome (STEMI, NSTEMI) 3. Capability of providing written informed consent 4. Patients able to comply with the follow-up schedule of the study Exclusion Criteria: 1. Patients with acute coronary syndromes classified as MINOCA, or type II myocardial infarction 2. Patients with rare acute coronary syndrome types, such as spontaneous coronary artery dissection or Takotsubo syndrome 3. Patients with congenital heart disease 4. Age \> 85 years 5. Patients with end stage chronic kidney disease 6. Patients with active malignancy or autoimmune diseases which limit their survival 7. Patients with expected survival \< 1 year due to other reasons 8. Suboptimal echocardiographic windows 9. Inability to provide written consent 10. Inability to comply with the follow-up schedule of the study 11. Pregnancy 12. Use of intravenous drugs

Contact & Investigator

Central Contact

Christodoulos E. Papadopoulos, PhD

✉ chrpapado@gmail.com

📞 2313312343

Principal Investigator

Christodoulos E. Papadopoulos, PhD

PRINCIPAL INVESTIGATOR

Aristotle University of Thessaloniki, Greece

Frequently Asked Questions

Who can join the NCT06890013 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 85 Years, studying Acute Coronary Syndromes. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06890013 currently recruiting?

Yes, NCT06890013 is actively recruiting participants. Contact the research team at chrpapado@gmail.com for enrollment information.

Where is the NCT06890013 trial being conducted?

This trial is being conducted at Thessaloniki, Greece.

Who is sponsoring the NCT06890013 clinical trial?

NCT06890013 is sponsored by Aristotle University Of Thessaloniki. The principal investigator is Christodoulos E. Papadopoulos, PhD at Aristotle University of Thessaloniki, Greece. The trial plans to enroll 100 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology